http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
-
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
-
Merck (MRK) Announces EU Approval of KEYTRUDA Plus Chemotherapy for NSCLC
-
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Ca
-
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
-
Merck (MRK) Provides Update on Phase 3 KEYLYNK-006 Trial of KEYTRUDA Plus Maintenance LYNPARZA
-
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Can
-
MilliporeSigma Invests More than € 300 Million in New Life Science Production Site in Korea
-
Merck (MRK) Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
-
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
-
Merck (MRK) Reports KEYTRUDA Plus Chemoradiotherapy Significantly Improved OS Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
-
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Can
-
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
-
Merck (MRK) Completes Acquisition of Harpoon Therapeutics
-
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
-
Gilead Sciences (GILD) and Merck (MRK) Report Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
-
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
-
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
-
Merck to Participate in the Barclays 26th Annual Global Healthcare Conference
-
Merck to Participate in the Leerink Partners Global Biopharma Conference 2024
-
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
-
Merck to Participate in the TD Cowen 44th Annual Health Care Conference
-
Merck (MRK) Reports Positive EU CHMP Opinion for KEYTRUDA in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectabl
-
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment
-
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
-
Merck Animal Health (MRK) Acquires Elanco’s (ELAN) Aqua Business for $1.3B Cash
-
Merck Animal Health to Acquire Elanco’s Aqua Business
-
Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results
-
Merck's (MRK) KEYTRUDA Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC)
-
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephr
-
Merck (MRK) Reports KEYTRUDA Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothel
-
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced
-
Merck Announces Second-Quarter 2024 Dividend
-
Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1
-
Merck Animal Health's Fourth Veterinary Wellbeing Study Indicates Progress in Addressing Mental Health Challenges Among Veterinary Teams
-
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer
-
Merck (MRK) to Acquire Harpoon Therapeutics (HARP) for $23/sh Cash or $680M
-
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline
-
Merck (MRK) Announces Phase 3 Trial Initiations for Four Investigational Candidates
-
Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline
-
Merck to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
-
Merck (MRK) Reports Patritumab Deruxtecan Granted Priority Review in the U.S.
-
Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
-
Merck (MRK) Receives CRL for Gefapixant
-
Merck Provides U.S. Regulatory Update on Gefapixant
-
Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference
-
Merck (MRK) Granted FDA Priority Review for V116
-
FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults
-
Merck (MRK) Announces EU Approval of KEYTRUDA Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS ≥1) and Advance
-
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (C